An Open Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Anetumab Ravtansine in Subjects With Mesothelin-expressing Advanced Solid Cancers and Different Stages of Concurrent Hepatic or Renal Impairment

Trial Profile

An Open Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Anetumab Ravtansine in Subjects With Mesothelin-expressing Advanced Solid Cancers and Different Stages of Concurrent Hepatic or Renal Impairment

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Anetumab ravtansine (Primary)
  • Indications Adenocarcinoma; Breast cancer; Fallopian tube cancer; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 11 Oct 2017 Planned primary completion date changed from 20 Mar 2018 to 20 Aug 2018.
    • 06 Sep 2017 Planned number of patients changed from 36 to 60.
    • 28 Aug 2017 Planned End Date changed from 23 May 2018 to 20 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top